COX-2: Where are we in 2003? - Distinction from NSAIDs becoming blurred by Day, Richard
116 CI = confidence interval; COX-2 = cyclooxygenase-2; CSI = COX-2-selective inhibitor; NSAID = nonsteroidal anti-inflammatory drug.
Arthritis Research & Therapy    Vol 5 No 3 Day
Introduction
There are several key issues concerning cyclooxygenase-2
(COX-2)-selective inhibitors (CSIs) for 2003:
1. What exactly are CSIs and how are they differentiated
from nonsteroidal anti-inflammatory drugs (NSAIDs)?
2. Is there a problem concerning the cardiovascular
safety of CSIs?
3. What is the clinical approach to coprescribing low-
dose aspirin and CSIs?
4. What is the merit, if any, of coprescription of gastro-
protective agents such as proton-pump inhibitors in
patients at high risk of upper gastrointestinal adverse
effect from anti-inflammatory drugs including CSIs?
5. Are CSIs safe in patients with aspirin sensitivity?
What do we mean by ‘COX-2-selective
inhibition’ and does this term have clinical
significance?
We now have second-generation CSIs: valdecoxib, pare-
coxib, lumiracoxib and etoricoxib. However, there are unre-
solved issues with this class of drug.
Defining a CSI has become increasingly difficult. Some
NSAIDs of characteristic weak acidic chemical nature,
such as diclofenac and meloxicam, display some degree
of ‘selectivity’ for inhibition of human COX-2 in compari-
son with COX-1, as has been shown in appropriate whole-
blood-based  in vitro  assay systems [1,2], and yet
diclofenac is labelled an NSAID and meloxicam a CSI.
There are anti-inflammatory drugs that have a reputation
largely based on spontaneous reports, case–control or
cohort studies, or small, short, randomized, controlled
studies for lower rates of upper gastrointestinal toxicity.
Included in this category are drugs such as etodolac,
nimuleside and nabumetone, which also appear to display
some degree of ‘selectivity’ for COX-2. This problem of
classification and differentiation between CSI and NSAID
is confusing and affects prescribing decisions. It seems to
revolve around the following issues:
1. Whether the drug was deliberately designed to inhibit
the COX-2 isoenzyme using the identified structure of
the enzyme and its differentiation from the structure of
COX-1. This contrasts with the situation of COX-2
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selectivity being demonstrated for an NSAID that was
synthesized before knowledge of the structure of
COX-2 (for example, diclofenac and meloxicam were
not designed to specifically inhibit COX-2, whereas
celecoxib and rofecoxib were).
2. The degree of rigour in testing the hypothesis that a
purported CSI is markedly superior to conventional,
dual inhibitors of COX-1 and COX-2 in respect of
upper gastrointestinal toxicity. Rofecoxib and celecoxib
have been subject to much sterner tests of relative
gastrointestinal safety than other NSAIDs; these tests
include endoscopic and outcome studies using very
high dose rates relative to clinically recommended
doses, long durations of exposure to drugs during
these tests and substantial numbers of patients [3–5].
3. Some agencies, with the remit of determining the
quality of the ‘evidence base’ behind claims of superi-
ority and incremental cost–benefit, perhaps undervalu-
ing some issues of study design: duration, number of
subjects, and doses of drugs used.
As we have learned painfully in other areas of therapeu-
tics, the proper test of a drug is in demonstrated health
outcomes of value. Reduction of the serious morbidity and
mortality accruing from adverse effects of NSAIDs on the
upper gastrointestinal tract has been an appropriate target
for improvement for many years. Largely on the basis of
the VIGOR study [3], the FDA has approved an alteration
to the rofecoxib label indicating that it is safer for the gas-
trointestinal tract than are conventional NSAIDs. This
study, in over 8000 patients with rheumatoid arthritis,
showed a 50–60% reduction in the rate of confirmed, clin-
ically important upper gastrointestinal events, namely per-
foration, obstruction, symptomatic peptic ulceration and
serious upper gastrointestinal bleeding. This contrast was
demonstrated at a dose of rofecoxib twice that recom-
mended for the treatment of rheumatoid arthritis (50mg
daily), the patients being followed for a median of
9 months, in comparison with a full anti-inflammatory dose
of naproxen (1500mg daily) [3]. Expressed another way,
there were 2.09 versus 4.49 events per 100 patient years
of therapy in rofecoxib and naproxen, respectively, which
is a highly significant difference. Even though double the
upper recommended dose of rofecoxib was used, this
finding translates to 41 patients needing to be treated with
rofecoxib (50mg/day) to avoid one clinically significant
upper gastrointestinal event per annum versus naproxen
(1500mg/day).
A similar alteration to the celecoxib label has not been
allowed by the FDA, because of various problems sur-
rounding the design, analysis, and publication of the
CLASS study and the FDA analysis of the complete data
from the study [4,5]. Subsequent studies increasingly indi-
cate that celecoxib has a significant gastrointestinal
advantage over conventional NSAIDs, as would be
expected on the basis of extensive endoscopy studies
[6,7]. However, in patients at very high risk of recurrent
bleeding, celecoxib (200 mg twice daily) did not protect
better than diclofenac (150 mg daily) plus omeprazole
(20mg daily), the risk of rebleeding being 4.9% for cele-
coxib (confidence interval [CI] 3.1–6.7) versus 6.4 for
diclofenac plus omeprazole (CI 4.3–8.4), suggesting sub-
stantial room for improvement in this group of patients [8].
There is a continuum from the NSAIDs that are relatively
selective for COX-1, to those that are ‘dual inhibitors’ of
COX-1 and COX-2, on to those that show increasing rela-
tive selectivity for COX-2, and ending in those drugs, such
as rofecoxib and the second-generation COX-2 inhibitors
such as etoricoxib, that are highly selective for COX-2 [2].
This designation needs to be undertaken fairly and rigor-
ously, using appropriate whole-blood-based in vitro systems
[1,2,9]. In order to deal with the increasing confusion gener-
ated by claims of selectivity, the resultant ratio is best
regarded as a surrogate indicator only. The designation
‘CSI’ should indicate a drug that not only shows substantial
selectivity  in vitro  and preferably ex vivo  using the whole
blood assays for COX-1 and -2, but also substantial differ-
entiation from conventional NSAIDs with respect to upper
gastrointestinal damage in reasonably long studies of endo-
scopic and gastrointestinal outcomes. Most importantly, dif-
ferentiation should be demonstrated at drug doses of at
least the maximum recommended, or well above those
expected to be used to control inflammation [5]. With this
approach, clinicians could have confidence that the label
CSI translates into a drug with a definite advantage in gas-
trointestinal safety across the whole dosage spectrum.
Unfortunately, such clarity does not exist today.
Cardiovascular safety
Concern continues regarding the cardiovascular safety of
highly selective CSIs, because of the unexpected but sig-
nificantly higher rate of cardiovascular thrombotic events
with rofecoxib than with naproxen seen only in the VIGOR
study [10]. The theoretical rationale for concern has been
boosted by the work of Cheng and colleagues using
knock-out animals, who showed that not only is endothe-
lial COX-2-derived prostacyclin inhibited by CSIs, but also
its relative reduction by CSIs results in a ‘disinhibition’ of
thromboxane production from platelets [11].
Thromboxane A2 unopposed by prostacyclin in individuals
with increased risks of cardiovascular thrombosis is a
concern with enough evidence to be reflected in an FDA-
mandated recent label change for rofecoxib. Furthermore,
case reports indicate that patients with thrombophilic con-
ditions are at risk from CSIs, and the labels for both rofe-
coxib and celecoxib reflect this.
Increasing comfort has been taken from large-scale meta-
analyses of clinical trials programmes of celecoxib and
rofecoxib [12–14]. Thus, a recent review of the clinical118
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trial database for rofecoxib in over 28,000 patients con-
cluded that rofecoxib was not different from non-naproxen
NSAIDs but that naproxen might be providing cardiovas-
cular protection, at least in rheumatoid arthritis. However,
as noted, the FDA has added a description of the cardio-
vascular findings in the VIGOR study to the label for rofe-
coxib along with a statement urging “caution in patients
with a medical history of ischaemic heart disease…” [15].
Meanwhile, it has become apparent that chronic inflamma-
tion as seen in rheumatoid arthritis is an important risk
factor for thrombotic cardiovascular adverse events, deliv-
ering a relative risk of the order of 2.
Resolution of this important issue of safety of CSIs in indi-
viduals with various degrees of risk for thrombotic events
requires large-scale, event-driven, randomized, controlled
trials versus conventional NSAIDs in patients with known
background cardiovascular risk factors. These studies
need to be undertaken in patients properly managed with
respect to their cardiovascular risk with appropriate
antiplatelet therapy. Also, careful consideration needs to be
given to the exclusion criteria, in order to assure that a
lower-risk population is not studied. The second-generation
CSIs such as etoricoxib and valdecoxib, which are more
selective for COX-2 than first-generation CSIs [16], should
be able to inform us properly about the cardiovascular risks
of highly selective inhibition of COX-2 versus COX-1.
COX-2-selective inhibitors and concomitant
low-dose aspirin
A surprising finding from the CLASS study was that in the
21% of patients taking prophylactic low doses of aspirin,
the relative protection from serious upper gastrointestinal
bleeding and perforation versus the NSAIDs ibuprofen
and diclofenac was lost [4]. Aspirin, even in low, prophy-
lactic cardiovascular doses, is known to increase the risk
of serious bleeding from the upper gastrointestinal tract
2-to 4-fold [17]. However, it is also well known that there
is a dose response for NSAIDs and the risk of serious
upper gastrointestinal bleeding [18,19]. One would
expect that aspirin plus an NSAID would lead to more
serious upper gastrointestinal adverse effects than aspirin
plus a CSI and that the rate for aspirin plus a CSI would
be similar to that expected from aspirin alone. Indeed,
Weil et al. demonstrated a relative risk of 3.3 for aspirin
alone (CI 2.5–4.4), of 4.9 for NSAIDs alone (CI 3.9–6.1)
and of 7.7 for aspirin plus NSAID (CI 3.6–16.4); however,
the study suffered obviously from lack of power [17].
Therefore, one would expect aspirin plus a CSI to be
associated with less bleeding than aspirin plus an NSAID.
A number of subsequent studies have suggested that this
may be the case [6,7], in contrast to the unexpected find-
ings in the CLASS study.
Again, definitive studies based on clinically important gas-
trointestinal outcomes are required to resolve this issue.
Until such studies have been done, individuals with identi-
fied cardiovascular risk factors requiring platelet inhibitory
therapy should get it. As our estimation of the risk of upper
gastrointestinal haemorrhage increases, then it is reason-
able that our inclination to use a CSI instead of an NSAID
should increase. Importantly, there are no data to show
that in this clinical situation celecoxib or rofecoxib, unlike
ibuprofen, blocks the actions of aspirin on the platelet
[20].
Coprescription of gastroprotective agents
As the risk for gastrointestinal bleeding and perforation
increases in patients, and in situations where treatment
with an anti-inflammatory analgesic drug would be helpful,
prescribers are increasingly coprescribing gastroprotec-
tive agents. This is logical if we extrapolate from the pivotal
studies indicating a protective effect for proton-pump
inhibitors when NSAIDs are used [21]. The question of
whether these drugs add to the protective effect of the
CSIs remains moot but is worthy of elucidation for the pro-
portion of patients for whom such an approach might be
reasonable.
COX-2-selective inhibitors in patients with
hypersensitivity to aspirin?
A number of studies now confirm that the CSIs rofecoxib
and celecoxib are very much less likely than conventional
NSAIDs to be associated with hypersensitivity reactions in
patients with known hypersensitivity to aspirin [22–24].
However, because of the heterogeneity of the aspirin
hypersensitivity syndrome, great caution still needs to be
taken if prescribing CSIs in this situation. Cases of
angioedema have been reported [25]. Use of the most
selective members of the CSI class would seem wise.
Conclusion
The CSIs have been the source of great interest and
advance in rheumatology. A clearer picture of the clinical rel-
evance of the CSIs in contrast to NSAIDs is emerging. The
risk of thrombotic cardiovascular events with CSIs in
patients with risk factors for thrombotic events needs further
elucidation. Uncertainties concerning the use of CSIs con-
comitant with gastroprotective agents in patients taking low
doses of aspirin prophylactically and in patients with a
history of aspirin hypersensitivity need resolution. The emer-
gence of the CSIs has led to rheumatology becoming more
closely intertwined with cardiovascular medicine. Also,
methodologies of clinical trials have advanced significantly
as a consequence of the introduction of CSIs. However,
there is much more to be revealed in 2003.
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